SOUTH SAN FRANCISCO, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company has added three new executives to its leadership team: senior vice president, governmental affairs and chief legal officer, Ashley Gould, senior vice president, Corporate and Business Development, Natalie Holles and vice president, Investor Relations and Corporate Communications, Sylvia Wheeler.
"I am pleased with the varied breadth of related industry expertise each of these individuals brings to our business," said Donald J. Santel, Chief Executive Officer of Hyperion. "As we continue to mature as a company, their respective experience and skills will be instrumental in helping to guide our growth as a commercial enterprise seeking to deliver life-changing treatments to the patient and medical communities we serve."
Senior Vice President, Governmental Affairs and Chief Legal Officer; Ashley GouldMs. Gould will be responsible for serving as the company's in-house legal counsel and leading public and governmental affairs activities. Ms. Gould recently served as vice president, Corporate Development and chief legal officer at 23andMe, a personal genetics company. Prior to joining 23andMe in 2007, Ms Gould was vice president, Legal Affairs at CoTherix, Inc., a biopharmaceutical company. Previously, Ms. Gould was associated with the law firms of Wilson Sonsini Goodrich & Rosati PC and O'Melveny & Myers LLP. Ms. Gould received her JD from the University of San Francisco School of Law and her B.S. in Political Economy of Natural Resources from the University of California, Berkeley. Senior Vice President, Corporate and Business Development; Natalie Holles Ms. Holles will lead Hyperion's efforts to bring in new products to complement the existing portfolio and identify other ways to grow the company through external industry relationships. For the past five years, Ms. Holles has worked as an executive-level consultant leading business development activities for several life sciences companies. Most recently she served as executive vice president of Corporate Development for Immune Design, a leading cancer immunotherapy company based in Seattle. Ms. Holles also brings extensive in-house business development experience from KAI Pharmaceuticals, and InterMune, Inc. Ms. Holles began her career in the industry as a Marketing Planning Associate at Genentech, Inc. Ms. Holles received her M.A. in Molecular, Cellular and Developmental Biology from the University of Colorado and her A.B. in Human Biology from Stanford University.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV